In the News April 9, 2021

Inside Health Policy, Inside Drug Pricing | FDA: Inspection Lag Puts Generic Drug Exclusivity at Risk

Cathy Burgess and Natalie Clayton are quoted on the backlogs of onsite facility inspections by the U.S. Food and Drug Administration and how the delays put generic drug applications at risk.
Media Contact
Alex Wolfe
Communications Director

This website uses cookies to improve functionality and performance. For more information, see our Privacy Statement. Additional details for California consumers can be found here.